Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLN-978 in Moderate to Severe Systemic Lupus Erythematosus (SLE)
NCT06613360Phase 1Recruiting
- Sponsor
- Cullinan Therapeutics
- Start
- Jan 2025
- Primary completion
- Dec 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 9
01
Overview
Phase 1, open-label trial of CLN-978 in systemic lupus erythematosus (SLE) (2 arms), sponsored by Cullinan Therapeutics. Primary endpoint: Safety and tolerability at 48 weeks. Started Jan 2025; status: recruiting.
02
Drugs
CLN-978
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT06613360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06613360.